
Pathology Outlines - CD123
CD123 is a biomarker for targeted therapy in certain diseases, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (N Engl J Med 2019;380:1628, Clin Cancer Res …
Interleukin-3 receptor - Wikipedia
The interleukin-3 receptor (CD123) is a molecule found on cells which helps transmit the signal of interleukin-3, a soluble cytokine important in the immune system. The gene coding for the receptor is located in the pseudoautosomal region of the X and Y chromosomes.
CD123 as a Biomarker in Hematolymphoid Malignancies: …
CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy …
CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Emerging studies demonstrate that CD123, the interleukin 3 receptor alpha (IL-3Rα), is highly expressed in LSCs, while not normal hematopoietic stem cells (HSCs), and associates with treatment response, minimal residual disease (MRD) detection and prognosis.
CD 123 is a membrane biomarker and a therapeutic target in …
2014年2月10日 · This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia.
CD123 as a Therapeutic Target in the Treatment of Hematological ...
2019年9月12日 · Importantly, CD123 is expressed at both the level of leukemic stem cells (LSCs) and more differentiated leukemic blasts, which makes CD123 an attractive therapeutic target. Various agents have been developed as drugs able to target CD123 on malignant leukemic cells and on the normal counterpart.
CD123 as a Therapeutic Target in the Treatment of Hematological ...
CD123 targeting represents an effective therapeutic option for BPDCN patients and tagraxofusp, a drug based on a genetically engineered diphtheria toxin fused with IL-3, has shown robust activity and BPDCN was the first IL-3Rα targeting agent approved for the treatment of a hematological malignancy.
CD123 Expression Is Associated With High-Risk Disease …
2021年12月2日 · CD123 is a critical biomarker and promising immunotherapeutic target for children with relapsed or refractory AML, given its prevalent expression and enrichment in patients with high-risk genetic alterations and inferior clinical outcomes with conventional therapy.
Targeting CD123 in hematologic malignancies: identifying suitable ...
2021年5月17日 · Following the observation of interleukin 3 receptor α chain (IL-3Rα; CD123) upregulation on leukemia stem cells (LSCs) almost two decades ago, targeted treatment via CD123-diptheria toxin conjugates has now been tested in …
Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 …
2024年11月5日 · Vibecotamab is a CD3-CD123 bispecific engaging antibody with clinical activity in relapsed/refractory AML, particularly in low-blast disease. We therefore sought to evaluate vibecotamab in other low-blast states: MDS or CMML after hypomethylating agent (HMA) failure and MRD-positive AML.